Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio...
Yahoo! Finance: News
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
Zacks
Allogene Therapeutics Q1 2026 Earnings Call Transcript
read more...
Benzinga
Allogene Therapeutics (ALLO) Projected to Post Quarterly Earnings on Tuesday
Allogene Therapeutics (NASDAQ:ALLO) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-allogene-therapeutics-inc-stock...
MarketBeat
Annie Yoshiyama Sells 9,586 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average...
MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) SVP Annie Yoshiyama sold 9,586 shares of the company's stock in a transaction dated Tuesday, April 21st. The stock was sold at an average...
MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6% - Should You Sell?
Allogene Therapeutics (NASDAQ:ALLO) Trading Down 6% - What's Next...
MarketBeat
HC Wainwright Issues Optimistic Estimate for ALLO Earnings
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at HC Wainwright boosted their Q2 2026 EPS estimates for Allogene Therapeutics in a report released on Thursday, April 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.15) per share for th...
MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat...
MarketBeat

Advertisement|Remove ads.